Sugi Predict
/ Targets
/ PTK2B
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to PTK2B by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis |
PHASE4 | NOT_YET_RECRUITING |
| The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway |
PHASE4 | COMPLETED |
| The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus |
PHASE3 | UNKNOWN |
| Platelet Rich Plasma in Treatment of Melasma |
PHASE3 | UNKNOWN |
| ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy |
PHASE2 | COMPLETED |
| Neoadjuvant GW572016 to Treat Breast Cancer |
PHASE2 | COMPLETED |
| Phase II Study of Vandetanib in Individuals With Kidney Cancer |
PHASE2 | COMPLETED |
| Imatinib in Dermatofibrosarcoma Protuberans (DFSP) |
PHASE1/PHASE2 | COMPLETED |
| Selective Treatment According to Molecular Subtype of Prostate Cancer |
PHASE2 | UNKNOWN |
| Protein Tyrosine Kinases (PTK) in Multiple Myeloma |
PHASE2 | COMPLETED |
| Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients |
PHASE2 | ENROLLING_BY_INVITATION |
| PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP |
PHASE1/PHASE2 | COMPLETED |
| Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma |
PHASE2 | COMPLETED |
| Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
PHASE1/PHASE2 | COMPLETED |
| Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 |
PHASE1 | COMPLETED |
| A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors |
PHASE1 | COMPLETED |
| FAK Inhibitor in Patients With Advanced Solid Tumors |
PHASE1 | NOT_YET_RECRUITING |
| Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing |
PHASE1 | COMPLETED |
| Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 |
PHASE1 | WITHDRAWN |
| Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer |
PHASE1 | COMPLETED |
| Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration |
PHASE1 | COMPLETED |
| The Clinical Application of 68Ga Labeled ssDNA Aptamer Sgc8 in Healthy Volunteers and Colorectal Patients |
EARLY_PHASE1 | UNKNOWN |
| Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer |
nan | RECRUITING |
| Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma |
nan | COMPLETED |
| Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA |
nan | RECRUITING |
| NTRK 1,2,3 Rearrangements in Patients With Solid Tumors |
nan | ACTIVE_NOT_RECRUITING |
| p-AKT Expression on Clinical Outcomes in Malignant Lymphoma |
nan | COMPLETED |
| K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications |
nan | COMPLETED |
| Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a PTK2B binder may also engage these)